FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

3235-0287 OMB Number: Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							. ,												
Name and Address of Reporting Person* Mond James						2. Issuer Name and Ticker or Trading Symbol ADMA BIOLOGICS, INC. [ADMA]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
Mond James																Director		10% C	Owner
(Last) (Einst) (Middle)					- 2 5	Date of Earliest Transaction (Month/Day/Year)										Officer (gi below)	jive title	Other below	(specify)
(Last) (First) (Middle)							11/09/2017									EV	P, CSO	and CMO	
C/O ADMA BIOLOGICS, INC.						11/05/2017													
465 STATE ROUTE 17																			
						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable				
(Street)															Line)				
RAMSEY NJ 07446														X Form filed by One Reporting Person					
				-										Form filed by More than One Reporting Person					
(City)	(St	ate) (Zip)																
		Tabl	e I - No	n-Deriv	/ative	Se	curitie	s Acc	quired,	Dis	posed o	f, or	Bene	efici	ally O	wned			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da						Execution Date,			Code (Transaction Disposed Of (D) Code (Instr. 5)			s Acquired (A) or f (D) (Instr. 3, 4 an		and Securities Beneficiall Owned Fol		Fo ly (D)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
									Code	v	Amount		(A) or (D)	Price	, т	eported ransactior nstr. 3 and			(Instr. 4)
Common Stock 11/09/2						/2017			P		10,000	(1)	A	A \$2.15		5 13,389		D	
		Та									osed of, onvertib				y Owr	ned	•		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Executior if any (Month/Da	n Date,	4. Transaction Code (Instr. r)		n of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		str. 3	8. Price Deriva Securi (Instr. !	tive deri ty Sec 5) Ben Owr Foll Rep Trar	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	or Nun of						

Explanation of Responses:

1. Represents a purchase from the underwriters in the Issuer's public offering.

/s/ James Mond, by Brian Lenz 11/13/2017 as Attorney-in-fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.